Pulmatrix is committed to developing breakthrough technologies for the treatment of pulmonary disease. With the novel iSPERSE pipeline, Pulmatrix has the ability to develop single and combination therapies that will provide advances in current standard of care and novel drug formulations that will improve patient outcomes, compliance, and convenience. Pulmatrix is particularly focused on improving the lives of patients and chronic respiratory diseases including:
In addition, Pulmatrix is focused on developing superior approaches for pulmonary indications of particular unmet need including:
- Idiopathic Pulmonary Fibrosis (IPF)
- Non-CF Bronchiectasis (NCFBE)
The lead clinical iSPERSE compound, PUR118, is intended for broad-spectrum efficacy of the iCALM technology supporting administration as a treatment or preventative measure for airway inflammation, or even as a first-line of defense to respond to traditional and emerging infectious agents. This technology could provide a unique breakthrough approach to preventing and reducing the severity of debilitating acute exacerbations in patients with progressive respiratory diseases like COPD and CF.